Verastem Oncology doses first patient in TARGET-D 203 Phase 2 trial

The registration-directed study is evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D-mutated metastatic colorectal cancer.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.